Literature DB >> 29398799

Evaluating New Markers for Minimal Residual Disease Analysis by Flow Cytometry in Precursor B Lymphoblastic Leukemia.

Sonal Jain1, Anurag Mehta1, Gauri Kapoor2, Dinesh Bhurani3, Sandeep Jain2, Narendra Agrawal3, Rayaz Ahmed3, Dushyant Kumar1.   

Abstract

Minimal residual disease is currently the most powerful prognostic indicator in Precursor B lymphoblastic leukemia. Multiparameter flow cytometry is the most commonly used modality. Seventy three B ALL cases and 15 normal marrows were evaluated for expression patterns of leukemia markers (CD38, CD58, CD73) in all 73 cases and CD66c, CD86 and CD123 in 23 cases. CD73 was aberrantly expressed in 90.41% cases and CD86 in 60.87% B ALL cases. Thus addition of these markers in MRD panels can increase the sensitivity of the assay.

Entities:  

Keywords:  Acute leukemia; Hematology; MRD

Year:  2017        PMID： 29398799      PMCID： PMC5786637          DOI： 10.1007/s12288-017-0845-5

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


  12 in total

1.  Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country.

Authors:  Nikhil Patkar; Ansu Abu Alex; Bargavi B; Rayaz Ahmed; Aby Abraham; Biju George; Auro Vishwabandya; Alok Srivastava; Vikram Mathews
Journal:  Cytometry B Clin Cytom       Date:  2012-03-29       Impact factor: 3.058

2.  The application of CD73 in minimal residual disease monitoring using flow cytometry in B-cell acute lymphoblastic leukemia.

Authors:  Wei Wang; Li Gao; Yan Li; Zhen-Ling Li; Ming Gong; Fan-Zhou Huang; Yan-Rong Chen; Chun-Xia Zhang; Ya-Yue Gao; Yi-Gai Ma
Journal:  Leuk Lymphoma       Date:  2015-10-05

3.  Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.

Authors:  Prashant R Tembhare; Sitaram Ghogale; Nisha Ghatwai; Yajamanam Badrinath; Nikesh Kunder; Nikhil V Patkar; Asma R Bibi; Gaurav Chatterjee; Brijesh Arora; Gaurav Narula; Shripad Banawali; Nilesh Deshpande; Prathibha Amare; Sumeet Gujral; Papagudi G Subramanian
Journal:  Cytometry B Clin Cytom       Date:  2016-10-27       Impact factor: 3.058

4.  Has MRD monitoring superseded other prognostic factors in adult ALL?

Authors:  Monika Brüggemann; Thorsten Raff; Michael Kneba
Journal:  Blood       Date:  2012-10-02       Impact factor: 22.113

5.  Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia.

Authors:  Nathalie Dhédin; Anne Huynh; Sébastien Maury; Reza Tabrizi; Kheira Beldjord; Vahid Asnafi; Xavier Thomas; Patrice Chevallier; Stéphanie Nguyen; Valérie Coiteux; Jean-Henri Bourhis; Yosr Hichri; Martine Escoffre-Barbe; Oumedaly Reman; Carlos Graux; Yves Chalandon; Didier Blaise; Urs Schanz; Véronique Lhéritier; Jean-Yves Cahn; Hervé Dombret; Norbert Ifrah
Journal:  Blood       Date:  2015-01-13       Impact factor: 22.113

6.  Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia.

Authors:  E Coustan-Smith; F G Behm; J Sanchez; J M Boyett; M L Hancock; S C Raimondi; J E Rubnitz; G K Rivera; J T Sandlund; C H Pui; D Campana
Journal:  Lancet       Date:  1998-02-21       Impact factor: 79.321

7.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.

Authors:  H Cavé; J van der Werff ten Bosch; S Suciu; C Guidal; C Waterkeyn; J Otten; M Bakkus; K Thielemans; B Grandchamp; E Vilmer
Journal:  N Engl J Med       Date:  1998-08-27       Impact factor: 91.245

8.  Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

Authors:  J J van Dongen; T Seriu; E R Panzer-Grümayer; A Biondi; M J Pongers-Willemse; L Corral; F Stolz; M Schrappe; G Masera; W A Kamps; H Gadner; E R van Wering; W D Ludwig; G Basso; M A de Bruijn; G Cazzaniga; K Hettinger; A van der Does-van den Berg; W C Hop; H Riehm; C R Bartram
Journal:  Lancet       Date:  1998-11-28       Impact factor: 79.321

9.  Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study.

Authors:  M J Borowitz; D J Pullen; J J Shuster; D Viswanatha; K Montgomery; C L Willman; B Camitta
Journal:  Leukemia       Date:  2003-08       Impact factor: 11.528

10.  Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia.

Authors:  Elaine Coustan-Smith; Jose Sancho; Frederick G Behm; Michael L Hancock; Bassem I Razzouk; Raul C Ribeiro; Gaston K Rivera; Jeffrey E Rubnitz; John T Sandlund; Ching-Hon Pui; Dario Campana
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113
View more
  2 in total

1.  Expression of CD73 on leukemic blasts increases during follow-up - a promising candidate marker for minimal residual disease detection in pediatric B-cell precursor acute lymphoblastic leukemia.

Authors:  Łukasz Słota; Łukasz Sędek; Jan Kulis; Bartosz Perkowski; Iwona Malinowska; Joanna Zawitkowska; Bernarda Kazanowska; Katarzyna Derwich; Maciej Niedźwiecki; Agnieszka Mizia-Malarz; Katarzyna Muszyńska-Rosłan; Andrzej Kołtan; Grażyna Karolczyk; Katarzyna Machnik; Tomasz Urasiński; Monika Lejman; Wanda Badowska; Wojciech Młynarski; Jerzy Kowalczyk; Tomasz Szczepański
Journal:  Cent Eur J Immunol       Date:  2022-03-17       Impact factor: 1.634

2.  Upregulation of CD146 in Pediatric B-Cell Acute Lymphocytic Leukemia and Its Implications on Treatment Outcomes.

Authors:  Asmaa M Zahran; Omnia El-Badawy; Khalid I Elsayh; Wael M Y Mohamed; Khalid F Riad; Mona H Abdel-Rahim; Amal Rayan
Journal:  J Immunol Res       Date:  2020-02-08       Impact factor: 4.818
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.